Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - zoledronic acid monohydrate - infusion - 50microgram/1ml

Malta - inglese - Malta Medicines Authority

ibigen s.r.l via fossignano, 2, 04011 aprilia (lt), italy - zoledronic acid, monohydrate - powder and solvent for solution for infusion - zoledronic acid monohydrate 4 mg/5ml - drugs for treatment of bone diseases

Malta - inglese - Malta Medicines Authority

1 a pharma gmbh - zoledronic acid monohydrate 4 mg/5ml - concentrate for solution for infusion

Malta - inglese - Malta Medicines Authority

1 a pharma gmbh - zoledronic acid monohydrate 5 mg - solution for infusion

Irlanda - inglese - HPRA (Health Products Regulatory Authority)

cipla (eu) limited - zoledronic acid monohydrate - solution for infusion - 5mg/100 millilitre - biphosphonates

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

dr reddy's laboratories (uk - zoledronic acid monohydrate - solution for infusion - 50microgram/1ml

Canada - inglese - Health Canada

taro pharmaceuticals inc - zoledronic acid (zoledronic acid monohydrate) - solution - 5mg - zoledronic acid (zoledronic acid monohydrate) 5mg - bone resorption inhibitors

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - zoledronic acid monohydrate 4.3mg equivalent to zoledronic acid 4 mg - concentrate for infusion - 4 mg/5ml - active: zoledronic acid monohydrate 4.3mg equivalent to zoledronic acid 4 mg excipient: mannitol sodium citrate dihydrate water for injection - prevention of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone) in patients with advanced malignancies involving bone

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - zoledronic acid monohydrate, quantity: 4.26 mg (equivalent: zoledronic acid, qty 4 mg) - injection - excipient ingredients: water for injections; sodium citrate dihydrate; mannitol - ? prevention of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone) in patients with advanced malignancies involving bone.,? treatment of tumour-induced hypercalcaemia (tih).,? as an adjunct to adjuvant treatment for women with early breast cancer who are in established menopause.

Stati Uniti - inglese - NLM (National Library of Medicine)

gland pharma limited - zoledronic acid (unii: 6xc1pad3kf) (zoledronic acid anhydrous - unii:70hz18ph24) - zoledronic acid anhydrous 5 mg in 100 ml - zoledronic acid injection is indicated for treatment of osteoporosis in postmenopausal women. in postmenopausal women with osteoporosis, diagnosed by bone mineral density (bmd) or prevalent vertebral fracture, zoledronic acid injection reduces the incidence of fractures (hip, vertebral and non-vertebral osteoporosis-related fractures). in patients at high risk of fracture, defined as a recent low-trauma hip fracture, zoledronic acid injection reduces the incidence of new clinical fractures [see clinical studies (14.1)]. zoledronic acid injection is indicated for prevention of osteoporosis in postmenopausal women [see clinical studies (14.2)]. zoledronic acid injection is indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.3)]. zoledronic acid injection is indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater